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Abstract
The zinc finger protein CF2 is a characterized activator of muscle structural genes in the body wall muscles of the Drosophila
larva. To investigate the function of CF2 in the indirect flight muscle (IFM), we examined the phenotypes of flies bearing five
homozygous viable mutations. The gross structure of the IFM was not affected, but the stronger hypomorphic alleles
caused an increase of up to 1.5X in the diameter of the myofibrils. This size increase did not cause any disruption of the
hexameric arrangement of thick and thin filaments. RT-PCR analysis revealed an increase in the transcription of several
structural genes. Ectopic overexpression of CF2 in the developing IFM disrupts muscle formation. While our results indicate
a role for CF2 as a direct negative regulator of the thin filament protein gene Actin 88F (Act88F), effects on levels of
transcripts of myosin heavy chain (mhc) appear to be indirect. This role is in direct contrast to that described in the larval
muscles, where CF2 activates structural gene expression. The variation in myofibril phenotypes of CF2 mutants suggest the
CF2 may have separate functions in fine-tuning expression of structural genes to insure proper filament stoichiometry, and
monitoring and/or controlling the final myofibril size.
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Introduction
The indirect flight muscles (IFM) of Drosophila are exquisitely
adapted to provide the maximum power to the wings. They
contain unique isoforms of structural proteins such as actin, the
troponins, and myosin heavy chain (mhc). Thick and thin filaments
are arranged in a distinctive hexagonal pattern (with each thick
filament surrounded by six thin filaments) that allows for
maximum contact between actin and myosin molecules. A number
of mutations in structural genes are known that allow relatively
normal development and functioning of other muscle types, but
severely disrupt IFM development and function. Some of these
mutations affect splicing of an IFM specific exon (for example the
hdp[3] mutation of troponin I (Tn I) [1]) or coding regions of genes
unique to the IFM (such as actin 88F (Act88F)), but some are null or
strong hypomorphic mutants of genes that are expressed in all
muscle types. For example, flies heterozygous for the Mhc[1] null
allele cannot fly, although heterozygous larvae have no discernable
locomotion phenotype and heterozygous adults can walk [2].
Likewise, flies lacking a copy of Act88F are flightless. Interestingly,
flies that are doubly heterozygous for null mutations in mhc and Act
88F (therefore having a 1:1 mhc: actin ratio) can fly, although not
as well as wild type (with a 2:2 ratio) [3]. Therefore, it is not just
the amounts of these proteins, but also their stoichiometry, that
influences flight muscle structure and function.
Sarcomeres assemble from the center outwards in the pupal
myotubes. The first thick and thin filaments can be detected at
about 42 hours after pupa formation (APF). Additional filaments
are added at the periphery until the myofibril reaches its final size
of approximately 35 thick filaments across (,1.5 mm in diameter)
in the late pupal stages [4]. Observations of myofibril assembly in
Act88F null mutants [3] or mhc null mutants [2] show that thin or
thick filaments can assemble in the absence of the other. Z-discs
can still form without the presence of thick filaments, and M-lines
can be observed if thin filaments are missing. But the presence of
both is required for normal sarcomere size, order, periodicity, and
consequentially function [3]. When filament stoichiometry is
altered, the peripheral regions of the myofibril tend to be the most
severely affected. When there is only one functional copy of mhc,
the thick filaments at the edges of the myofibril are surrounded by
9–10 thin filaments, instead of the normal six (which is maintained
in the central portions) [2]. Extra doses of mhc (the equivalent of
four copies) result in excess thick filaments at the periphery [5].
Since filament stoichiometry is so crucial to IFM development, it
should be very tightly controlled, but little is known about the
mechanisms that sense and adjust thick: thin filament ratios.
One point of control is the transcription of muscle structural
genes, and the actions of various transcription factors, particularity
in the embryonic stages, have been characterized. The MADS box
protein Mef2 is a major player in muscle differentiation. Binding
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myosin alkali light chain, and myosin light chain 2 in the embryonic
dorsal vessel [6], paramyosin/miniparamyosin in various muscles in
larvae and adults [7], Tn I in adult and embryonic muscle [8], and
tropomyosin 1 and 57B actin in embryonic muscles [9,10]. Chorion
factor 2 (CF2) encodes a Zn finger transcription factor, which was
first characterized as a repressor of dorsal fate in the follicle cells of
the ovary [11]. It is also expressed in the nuclei of all muscle types
of the embryo in a pattern similar to Mef2, being detectable at
around stage 12, after the induction of Mef2 expression [12]. CF2
was the first collaborating factor for Mef2 to be characterized [13].
The combination of Mef2 and CF2 has a synergistic effect on the
transcription of 57B actin, Tn I, and mhc in embryonic muscles [13],
and there are clusters of Mef2 and CF2 binding sites upstream of
troponin T, tropomyosin 1 and 2, and paramyosin [14]. But the role of
CF2 in development of the IFM remains undefined. Previous work
[14] reported impaired flight in two hypomorphic CF2 mutants,
but there have been no studies investigating what type of role CF2
plays in IFM development.
In this paper we investigate the regulatory role of the Zn finger
transcription factor CF2 in the development of the IFM. We show
that the specific isoforms expressed in the IFM changes during the
process of development, with pupal IFM expressing a different set
of CF2 isoforms than adult IFM. In contrast to its reported role in
embryonic and larval muscles, our data point to CF2 as a
repressor, rather than an enhancer, of at least one IFM structural
gene, Act88F. A reduction in CF2 function increases transcription
of several structural genes and in more severe cases increases
myofibril size. Gain of CF2 function has a deleterious effect on
IFM development, resulting in greatly reduced or almost
completely ablated muscles. Similar to its role in embryonic
muscle, CF2 in the IFM may be needed for the fine-tuning of
structural gene expression. Our data also suggests a role for CF2 in
insuring correct myofibril size.
Results
CF2 is expressed in adult and developing pupal flight
muscle
In the Drosophila embryo the CF2 protein is expressed in the
nuclei of all three muscle types (somatic, visceral, and dorsal vessel)
[12]. To determine whether the protein is also expressed in adult
flight muscle, we immunostained dissected IFM with a polyclonal
CF2 antibody (that detects all isoforms). As in the embryo, the
stain is distinctly nuclear (Fig. 1A), and its specificity confirmed by
a control with 2u antibody, but no 1u antibody (Fig. 1B). This
nuclear expression pattern is consistent with the conclusion that
CF2 is active in the IFM.
To examine the expression of CF2 transcript during develop-
ment of the flight muscles, we used RT-PCR on cDNA from the
dissected IFM of adults, 40 hr APF pupae (beginning of
myofibrilogenesis), and 60 hr APF pupae (elongation of IFM
complete). The primers used were designed to amplify all three
reported CF2 isoforms (Fig. 2A), which are created by alternative
splicing of exon 3 [15,16]. In the adult sample (Fig. 2B), only
isoforms I and II are detected. However, in both pupal lanes,
isoform III replaced isoform I. This result is confirmed by
Western blots (Fig. 2D–E). In the pupal samples the predominant
bands run at 53.5 kD and 56.3 kD, the expected sizes for
isoforms II and III. This suggests a previously unknown role for
isoform III, which had been reported to be only expressed in
testes [15]. In the wild type adult sample, a band the size of
isoform I (,56.7 kD) is observed instead of isoform III, consistent
with the PCR results.
We obtained four P-insertion mutant alleles of CF2 (dia-
grammed in Fig. 2C) (CF2[KG05342], CF2[KG08941, CF2[c04624]
and CF2[c01640], in fly lines referred to hereafter as 05342, 08941,
04624, and 01640). 05342, 08941, and 04624 have P-insertions 59
to the ATG start site in exon 2. The P-element in the 01640 line is
in exon 3, within sequences unique to isoform I. We generated a
fifth mutant (CF2[KG08941-R3] ), referred to hereafter as R3,b y
excision of the P-element from line 08941. The R3 mutant has a
small deletion (,2.7 kb) that removes the first exon of CF2, but
leaves the second exon (with the ATG start site) intact. All mutants
are homozygous viable, and exhibit no visible signs of IFM defects,
such as abnormal wing position. Western blots of mutant adult
thoraces reveal that four of the five mutations are hypomorphic,
ranging from the least severe, 05342, to the most severe, R3, which
has a greatly reduced level of all forms of CF2 as compared to wild
type (Fig. 2D–E).
The fifth mutant, 01640, has no detectable levels of isoform I.
There is one very strong band, but it does not match the sizes for
any of the other CF2 isoforms found in the other lanes. It runs
higher than isoform II, but lower than isoforms I and III. 01640 is
unique among the set of mutants in that it is the only one to have a
P-element insertion within coding sequences, in the region of exon
3 that is found only in isoform I. To test the possibility that the
01640 mutation produced an aberrant protein, we did RT-PCR
with several sets of primers designed to test the splicing of exon 3,
all CF2 isoforms, or the presence of P-element sequences (Fig. 2G).
With primers sets specific for isoform I or II (and 59 to the P
insertion site), the expected PCR products (386 bp and 361 bp)
are not observed in the mutant cDNA lanes, in contrast with the
wild type cDNA lanes. Primers from exons 2 and 3 upstream of
the P-site produce identical results (a 228 bp band) with both
genotypes, confirming that CF2 transcription is initiated in 01640
mutants. As expected, when primers for CF2 exon2 and the
PBac{PB} P-element vector [17] are used, a 328 bp PCR product
is found in the 01640 lane, but not the wild type lane. These results
confirm that exon 3 is not properly spliced in 01640 mutants, the
mRNA contains P-element sequences, and this likely produces a
truncated form of the CF2 protein.
Figure 1. CF2 exhibits nuclear localization in adult indirect
flight muscles. A) Flight muscles of a wild type adult, stained with
anti-CF2 antibody. B) Control staining without primary antibody.
Arrowheads indicate a representative nucleus in each panel.
doi:10.1371/journal.pone.0010713.g001
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The IFM of CF2 mutant adult flies appear normal on the gross
structural level, with no abnormalities in muscle number, size, or
patterning observed (data not shown). However, at the ultrastruc-
tural level, differences in myofibrils are seen between the wild type
and mutant flies (Fig. 3). In 05342, 08941, and 01640 myofibrils
(Figs. 3B, C, and F), the filament pattern often appeared diffuse.
The round shape of the myofibrils indicates a proper cross section
cut (as opposed to a section at an angle, which would produce an
oval shape to the myofibril), and filament patterns of simulta-
neously prepared wild type samples were clearly in focus (Fig. 3A).
In contrast, all mutants had clearly discernable sarcomeres in
longitudinal sections (data nor shown). R3 filaments were always
sharp and well defined, and these myofibrils showed no
abnormalities in filament pattern. Most 04624 filaments were also
easily visualized with a normal filament arrangement, although
they tended to be slightly less sharp than wild type or R3.
Myofibrils from CF2 mutants 08941, 04624, and R3 (Figs. 3C,
D, and E) are clearly larger than the wild type control (Fig. 3A).
We quantified the changes in myofibril size by counting thick
filaments in wild type, R3 and 04624 myofibrils, as these
measurements are less prone to any distortion during fixation
and cutting of the sections. A count of thick filaments from 13
randomly selected myofibrils from wild type, R3, and 04624
confirms this observation. Wild type myofibrils contained an
average of 802.9634.5 thick filaments, whereas 04624 and R3
averaged 1215.06120.6 (df=24, t=12.08, P,0.0005) and
1316.3664.1 (df=24, t=25.43, P,0.0005), respectively, a
statistically significant increase in myofibril size. Therefore a
certain threshold of CF2 function appears to be required to insure
the proper myofibril size.
CF2 loss of function increases the levels of mRNAs
encoding structural proteins
To determine the mechanism for the observed ultrastructural
phenotypes in some CF2 mutants, we examined expression of
several IFM structural genes via RT-PCR, using whole thoraces
(minus wings and legs). These results indicated elevations in
mRNA levels for most of the CF2 mutants (data not shown). To
verify and quantitate these results, we next performed qPCR on
cDNA from the five CF2 mutants and a wild type control, using
primers for Act88F, and the flight muscle specific isoforms of mhc
and Tn I. The results of the most consistent qPCR run are
diagrammed in a graph in Fig. 4A. The 08941 mutant showed the
most dramatic effects, averaging (over 2 separate runs) a 71-fold
increase in Act88F RNA levels, a 50-fold increase for mhc, and a 8-
fold increase for Tn I. The 05342 and 04624 mutants were the
next strongest by this measure. 05342 had average transcript
elevations of 18x, 7x, and 1.3x for Act88F, mhc, and Tn I; for
04624 the same RNA levels were up 7x, 20x, and 1.5x. The 01640
mutant had a weaker RNA phenotype, with Act88F up an average
,3.5x, mhc up 14x, and Tn I down 1.6x. The R3 transcription
phenotype was the mildest, with only a 1.7-fold increase in Act88F,
Figure 2. Expression patterns of CF2 isoforms in the IFM. A) Map of the CF2 gene, showing the location of the primers used for RT-PCR (red and
green arrows). These primers will amplify all three CF2 isoforms. Red regions denote coding sequences that are common to all three isoforms, purple
common to isoforms I and II, blue unique to isoform I, and green unique to isoform III. The lack of exon 3 in isoform III causes a frame shift in exon 4, so
that the green colored region, while present in all three isoforms, is in frame only for isoform 3. B) Gel of RT-PCR reactions with IFM cDNA from adults,
,40 hr pupae, and ,60 hr pupae. The predicted exon content of each band is indicated by the colored boxes on the left. All PCR products were
sequenced to confirm their exon content. C) Diagram of the CF2 gene and the sites of P-element insertions or genomic DNA deletion. The hatched bar
denotes the region that contains the R3 deletion. The exact breakpoints are unknown, but PCR mapping confirms that it is upstream of the ATG site. D)
Western blot of IFM protein from wild-type pupae and whole thorax protein from wild type and mutant adults, using a CF2 antibody. The red arrow head
points to the altered form produced by the 01640 mutant. E) Longer exposure of D), to show the fainter bands. F) Loading control Western using an actin
antibody. G) RT-PCR tests on mutant 01640 CF2 transcripts. Primers specific for isoforms I and II are 39 to the 01640 insertion site (See panel C), from exons
3a n d4 .Ap r i m e rs e t5 9 to the 01640 insertion site (from exons 2 and 3) was used to verify transcription of the CF2 gene. Testing for the presence of P-
element sequences used a primer from exon 2 and the PBac-3F2 primer [17]. 5C actin primers served as a loading control.
doi:10.1371/journal.pone.0010713.g002
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results were subjected to student’s t-test to verify statistical
significance, and with the exception of one of the R3 act88F
assays, all P values were 0.05 or lower. Quantitative PCR testing of
CF2 transcript levels in these mutants showed no significant
changes between the mutants and wild type, (data not shown).
To further verify that these effects are due to loss of CF2
function, we repeated this experiment with two CF2-RNAi lines,
expressed via an 88F-GAL4 driver (Figure 4B). CF2 specific
primers (which detect all isoforms) show that the RNAi construct
does indeed lower CF2 transcript levels, by over 50% 11924-R2
line, compared to the driver only control. The 11924-R3 line
increased Act88F transcript levels almost 2.5x, mhc over 1.5x, and
Tn I by almost 5 fold. These differences are not as great as those
observed between the stronger CF2 mutants and wild type, but the
88F-GAL4 has its own effects of muscle structural genes.
Compared to wild type, the driver alone caused elevations in
mRNA levels of the three structural genes tested, in addition to
CF2 itself (data not shown). Addition of a UAS-CF2-RNAi
construct reduced the levels of CF2 mRNA, but caused further
increases in Act88F, mhc, and Tn I transcripts, consistent with a
reduction of CF2 function increasing levels of structural gene
mRNAs. Taken together, analysis of six fly lines with altered CF2
function demonstrates that CF2 represses expression of these
muscle genes in the IFM.
CF2 overexpression disrupts IFM development
If CF2 has a role as a repressor in the IFM, then an increase in
function should cause a decrease in transcript levels of genes
encoding structural proteins. To test this hypothesis we overex-
pressed wild type and mutant (T40A) forms of CF2 using an IFM
specific GAL4 driver containing 1.3 kb of DNA upstream of
Act88F. This driver mimics the IFM expression of Act88F, with
expression first detected at around 40 hours APF. Ectopic CF2
expression caused major disruption of the IFM. Fig. 5A shows a
cross section through a wild type thorax, with its characteristic
indirect flight muscle pattern. When wild type CF2 is overex-
pressed (Fig. 5B), only a few shreds of muscle tissue can be found at
the dorsal part of the thorax; the majority of the space is empty of
any muscle tissue. The T40A mutant form (UAS-CF2[A40]),
which removes a phosphorylation site crucial to control of the
subcellular localization of CF2 (via nuclear export) [18] has an
even more severe effect (data not shown).
The use of two different GFP reporters produced two strikingly
different results. When an Act 88FGFP reporter was introduced
into these genetic backgrounds, there is no expression of GFP in
the CF2 gain of function, even in the remnants of muscle tissue
(Fig. 5D, wild type control Fig. 5C). In contrast, a mhc-GFP marker
is not affected. GFP expression is strong in the muscle remnants
(Fig. 5F, wild type control Fig. 5E), which are concentrated in the
dorsal and anterior most portion of the thorax. Examination of
developing IFM in pupa with overexpressed CF2[A40] and a mhc-
GFP marker revealed that much of the muscle tissue fails to
develop (Fig. 5G). The animal had reached to stage where its eyes
were pigmented, which makes it further along in its development
than the animals shown in the bottom panels of Figs. 5B and C,
yet those younger animals have a full set of IFM close to their final
size. We also tested a mhc-GAL4 driver (constructed with a 580 bp
IFM specific enhancer region upstream of mhc, see Fig. 6A) with
the UAS-CF2 constructs, and looked at the IFM of pharate adults.
The wild type CF2 produced a milder phenotype with this driver
(Fig 5H), with the IFM thinner than wild type (Fig. 5I), but intact
from anterior to posterior. Sections of these mutant thoraces
(Fig. 5L) confirmed that the IFM were considerably thinner than
Figure 3. Myofibril phenotypes of CF2 mutants. All pictures are cross sections through IFM tissue, with a magnification of 60,000X. A)
y w[67c23] B) CF2[KG05342] C) CF2[KG08941] D) CF2[KG08941-R3] E) CF2[c04624] F) CF2[c01640]. Scale bars are 500 nm.
doi:10.1371/journal.pone.0010713.g003
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produced IFM disruption as equally severe as seen with the 88F-
GAL4 driver (Fig. 5J), with only a few shreds of IFM expressing
RFP at the anterior of the thorax. These results demonstrate that
an excess of the CF2 transcription factor has a detrimental effect
on the development of IFM. The most likely cause is repression of
the transcription of structural genes. This is not currently directly
testable due to: 1) a reduction is muscle mass if excess CF2 is
expressed during muscle development, and 2) the lack of an
inducible system that does not have its own effect on structural
gene mRNAs. For example, when the GAL80[ts] system was tried
in order to induce excess CF2 after IFM development was
complete, the higher temperatures required caused a decrease in
IFM structural genes of control flies, making such an experiment
impossible to interpret (data not shown).
CF2 may not directly affect mhc transcription
Despite the effects of loss or gain of CF2 function on mhc
transcripts, expression of a mhc-GFP reporter is not affected by
overexpression of CF2. Since we did not know the precise location
of the sequences driving that reporter, we used a series of upstream
mhc reporters we had generated to examine more precisely the
effects of CF2 on mhc transcription in the IFM. We had previously
searched the 9 kb region upstream of mhc, using a series of
overlapping constructs for muscle (in particular IFM) enhancer
elements. Fig. 6A diagrams the location of regions that drive
muscle expression. Our analysis revealed a great diversity in both
spatial and temporal control of mhc expression. We found multiple
elements for a number of different muscle types (listed in Table 1),
and of most interest to us, three different types of IFM enhancers.
The first type of element (denoted as Class 1, diagrammed in red
in Fig. 6A) is expressed at the onset of myofibrilogenesis, in a
pattern reminiscent of the Act 88F GFP reporter (Fig. 6B
compares the two expression patterns). Expression in the IFM
remains strong throughout the adult life of the animal. A Class 2
element (diagrammed in blue in Fig. 6A) also expresses at the
beginning of myofibrilogenesis, but the expression is weaker, and it
diminishes to undetectable levels within a few days after eclosion.
Class 3 elements (diagrammed in green in Fig. 6A), are not
expressed until after the IFMs have finished elongating (Fig. 6C
compares this pattern with the Act 88F pattern).
We crossed a representative of each of the 3 types of mhc IFM
enhancer reporter lines into a CF2 gain of function background.
The Class 3 element we chose, F4-678, is also expressed in larval
somatic muscle, and has a putative CF2-II binding site (2381 to
2372) in close proximity to a putative MEF2 site (2412 to 2404).
It should be noted that constructs F4-728 and F4-678 are
contained within a region that has been previously tested for mhc
muscle enhancers [14,19]. All three types of enhancers continued
to drive GFP expression even when an excess of CF2 protein is
present (Fig. 6D). The muscle mass is clearly reduced, and
bunched at the anterior of the thorax, but still strongly expresses
GFP. Given the reduction of native mhc transcripts seen with
ectopic expression of CF2 (Fig. 5H), if direct repression by CF2
were the cause, we would expect to see an effect on at least one of
the mhc reporters. Our results suggest that a reduction in mhc
mRNA could be caused by a mechanism other than direct
transcriptional repression by CF2.
Discussion
In this paper we investigate the expression pattern and function
of the Zn finger transcription factor CF2 in adult flight muscle
Figure 4. Transcription of muscle structural genes is altered in CF2 loss of function mutants. Graphs of a representative qPCR run from A)
Five different CF2 mutant lines tested against a wild type strain, B) 88F-GAL4[81B-13]/+;11924-R3 CF2-RNAi/+ tested against 88F-GAL4[81B-13]/SM6.
** denotes differences from the control with a P-value #0.001. * denotes a P-value ,0.05.
doi:10.1371/journal.pone.0010713.g004
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IFM changes over time, with isoforms II and III present during
the building of the muscles, and isoforms I and II expressed in the
adult muscle. We have also characterized the IFM phenotypes of
CF2 mutants. In the loss of function mutants, transcripts of three
muscle structural genes (Act 88F, mhc, and Tn I) are increased, and
the stronger mutations cause an ,50% increase in myofibril size.
However the hexagonal arrangement of thick and thin filaments is
not perturbed. CF2 gain of function severely impairs the
development of the IFM, most likely by the downregulation of
structural genes. Lastly, our data point to CF2 as a probable direct
negative regulator of Act 88F, but possibly indirect regulator of mhc.
The exact nature (direct or indirect) of the effects of CF2 on Tn I
remains to be resolved.
Dynamic isoform expression pattern of CF2 in the IFM
During the early to mid stages of pupal development, when the
sarcomeres are still assembling, strong expression of isoforms II
and III at both the mRNA and protein level is observed in the
IFM, while isoform I replaces isoform III in the adult stage. This
represents a novel expression pattern for isoform III, which was
previously reported to be exclusive to the testes [15]. Our methods
(RT-PCR and Western blotting) are more sensitive than the
combination of PCR and Southern Blots used in this previous
study [15], and in addition we used material from dissected IFM
or thoraces rather than whole animals. Isoform III shares the first
three N-terminal zinc fingers found in isoforms I and II, but the
lack of exon 3 causes a frame shift that eliminates the C-terminal
zinc fingers. As zinc fingers 4, 5, 59, and 6 have been shown to be
Figure 5. CF2 gain of function disrupts IFM development. A) Cross section of the thorax of an 88F-GAL4[81B-13]/CyO fly (wild type control). B)
Cross section of the thorax of an 88F-GAL4[65-9]/UAS-CF2-II[wt]) fly. White arrows point to the remnants of the two dorsal-most dorsal longitudinal
muscles C) Expression of an 88F-GFP marker in wild type IFM (genotype 88F-GAL4[81B-13]/CyO). D) Expression of an 88F-GFP marker in IFM of fly
overexpressing wild type CF2 (genotype 88F-GAL4 [81B-13]/+; UAS-CF2-II[wt]). E) Expression of a mhc-GFP marker in wild type IFM (genotype 88F-
GAL4[65-9]/TM3, Sb). F) Expression of a mhc-GFP marker in IFM of fly overexpressing wild type CF2 (Genotype 88F-GAL4[65-9]/UAS- CF2-II[wt]). G)
Defects in muscle development in a 88F-GAL4[65-9]/UAS-CF2-II[A40] pupa. The age can be approximated by the presence of pigment in the eye
(indicated by the arrowhead. H) Pharate adult expressing UAS-CF2[wt] via a mhc-GAL4 driver. Arrowheads point to thinner IFMs. I) Control mhc-GAL4,
mhc-RFP animal, at the same stage as H and J. J) Pharate adult expressing UAS-CF2[A40] via a mhc-GAL4 driver. Arrows indicate the anterior remnants
of the IFM. K) Section through the thorax of a control fly expressing the mhc-GAL4 driver. L) Thoracic section of a fly expressing UAS-CF2-II[wt] via the
mhc-GAL4 driver. Arrowheads point to two of the abnormally thin dorso-lateral IFM.
doi:10.1371/journal.pone.0010713.g005
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bind DNA. However, the common three N-terminal zinc fingers
could facilitate protein-protein interactions. A possible function for
isoform III is to modulate the activity of isoform II, by sequestering
co-factors that bind the N-terminal region. Isoform III could be
needed to prevent isoform II from being too active (and thus
Figure 6. CF2 overexpression does not directly inhibit mhc transcription in the IFM. A) Map of the upstream region of mhc, showing
regions that drive muscle expression. Green bars (late IFM elements) denote elements that express later in IFM development (after ,70 hrs APF, class
3), red indicates an element (early IFM element) that is expressed at the onset of myofibrilogenesis (,40 hrs AFP at 22uC, class I), and blue an early
IFM element that ceases expression in early adulthood (class 2). The black bars denote enhancer elements that drive expression in muscle types other
than IFM. B) Expression patterns of GFP and RFP in animals carrying both the mhcF3-580-GFP early enhancer and an 88F-RFP reporter. C) Expression
patterns of GFP and RFP in animals carrying both the mhcF4-631-GFP late enhancer and an 88F-RFP reporter. D) Expression of the three different
classes of mhc reporters in a CF2 gain of function background.
doi:10.1371/journal.pone.0010713.g006
Table 1. Muscle expression patterns of upstream mhc enhancers.
Element Location Muscle Expression Pattern
mhcF2-479 27600 to 27111 larval somatic muscle, jump muscle (mid pupa-adult), IFM (mid pupal- adult)
mhcF2-510 27201 to 26692 larval somatic muscle, jump muscle (mid pupa-adult), IFM (mid pupal- adult)
mhcF2-491 26768 to 26278 subset of larval somatic muscles, leg muscle (pupa-adult)
mhcF3-580 25165 to 24586 IFM (40 hrs APF- adult), dorsal vessel (midpupa), subset of abdominal muscles and upperleg muscles
(pharate adult), proboscis muscles (late pupa)
mhcF3-548 23851 to 23303 jump muscle, dorsal vessel, leg muscle (pupa)
mhcF3-522 23360 to 22838 larval somatic muscle, proboscis muscles, leg, jump muscle (adult)
mhcF4-631 22158 to 21528 IFM (mid pupal- adult), dorsal vessel (midpupa)
mhcF4-728 26857 to 2913 larval somatic muscle, IFM (40 hrs APF-early adult)
mhcF4-678 21048 to 2371 larval somatic muscle, jump muscle (mid pupa-adult), IFM (mid pupal- adult), leg muscles, abdominal
muscles
mhcF4-453 2 485 to 233 larval somatic muscle, jump muscle (mid pupa-adult), IFM (mid pupal- adult), leg muscles, abdominal
muscles
Location refers to the position of the cloned sequences relative to the mhc transcription start site, which is considered to be position 0. Animals were examined at the
larval, pupal, and adult stages for GFP expression. All elements are diagrammed in Fig. 6A.
doi:10.1371/journal.pone.0010713.t001
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the adult IFM isoform III is replaced by isoform I. This isoform
has an extra DNA binding Zn finger. It preferentially binds a
12 bp consensus site [16], but it too may compete with isoform II,
for cofactors if not also for binding sites. Isoform I may be
functioning in a ‘‘maintenance mode’’ after the IFM myofibrils
have been built to their appropriate size. Earlier studies [14]
reported that the 05342 and 08941 mutant lines are flight
impaired, and this effect worsened with age. This phenotype could
be due to the lowered levels of isoform I in the IFM of these CF2
mutants.
Reconciling protein/transcript levels and ultrastructural
changes in CF2 mutant myofibrils
At first glance there looks to be a number of contradictions
between the Western, qPCR, and myofibrilar phenotypes of the five
different CF2 mutants. The Western blot data indicate a decreasing
hypomorphic series (based on amounts of CF2 protein) with
R3.04624$08941.05342. 01640, which produces an altered
protein, would fall outside this grouping. However, when effects
on the amounts of Act88F and mhc mRNAs are considered, the order
of severity is changed, with 08941.05342=04624.01640.R3.
The results from measurement of Tn I transcripts are more
complicated. The 08941, 05342,a n d04624 mutants all show
increased levels of Tn I transcripts. The opposite is observed with
01640 and R3, which cause a decrease in Tn I transcript levels.
Expression of CF2-RNAi in the IFM causes an increase in Tn I
mRNA, lending support to the hypothesis that a reduction in CF2
function caused increased transcription of Tn I (in addition to Act88F
and mhc). As mentioned above, 01640 is most likely not a simple
hypomorphic mutation. Given the presence of P-element sequences
in the CF2 mRNA of this mutant (Fig. 2G), and a band on the
Western blot (Figs. 2D and E), that does not correspond to any of
the three CF2 isoforms, it is most probable that the 01640 mutation
produces a truncated CF2 protein. The 01640 P insertion is within
the portion of exon 3 that is uniquely spliced into isoform I. The
coding sequences upstream, which include Zn fingers 1-4 (and half
of Zn finger 59) could reasonably be expected to be present in this
new CF2 protein. Such a protein could have changed functions,
which might account for the differences in effects on muscle gene
expression from those seen with the hypomorphic 08941, 05342,
and 04624 alleles.
Why does R3 appear to be the strongest CF2 mutant by protein
levels, but is the weakest when the effects of muscle gene
transcription are tested? The answer may be that it is not just a
CF2 hypomorph. R3 was produced by excision of the 08941 P-
element. Preliminary mapping via PCR analysis has indicated that
while the ATG site within exon 2 is intact, exon 1 is missing.
Furthermore, at least 2.7 kb of DNA upstream of exon 2 is also
missing. The nearest gene upstream of CF2, GC3008, is only
304 bp upstream of the CF2 transcription start site. Therefore the
R3 deletion will also affect this gene. CG3008 is predicted to be a
kinase (http://flybase.org/reports/FBgn0031643.html), but there
is no current data on its adult expression pattern or phenotypes of
any mutants. There are also several uncharacterized genes not far
downstream of CG3008 that could also be potentially affected by
the R3 deletion. There is no doubt that R3 affects CF2, given the
greatly reduced levels of CF2 protein and the enlarged myofibril
phenotype, but changes in any of these neighboring genes could
have their own effects on transcription in the IFM. These effects
could mitigate some of the effects of reduced CF2 in the R3 allele.
Further mapping of the R3 deletion and examination of these
neighboring genes should clarify this matter. In summary, 08941,
05342, and 04624, which produce increases in muscle gene
transcript levels that are in agreement with those produced by
RNAi knockdown, are hypomorphic mutations. 01640 is most
likely a neomorph, and R3, while a CF2 hypomorph, is also
mutant for at least one additional gene.
When considering the ultrastructural changes in CF2 mutants,
one correlation is unambiguous: the three lines with the greatest
reductions in CF2 protein (08941, 04624, and R3) are the ones
that display an enlarged myofibril phenotype. With the R3 and
04624 myofibrils, it is possible to get an accurate measure of the
increased size by counting the numbers of thick filaments. 08941
myofibrils appear to be comparable is size, but the lack of any
focus on distinct filament structures makes counting thick filaments
impossible. There is a weaker correlation here between the lack of
sharp filament structures and the increases in structural gene
transcription. 08941, which has the greatest increases in mRNA
levels, also has the ‘‘fuzziest’ myofibrils. The myofibrils of 05342
mutants, which have strong mRNA increases, also lack a clear
focus on filament structure. Instead of the hexameric pattern,
vague diamond or lines patterns are commonly observed instead.
Such patterns can be seen in wild type myofibrils cut at an angle,
as opposed to a 90u cross section. However such a cut would create
oval, as opposed to round, myofibril slices. Since the slices in our
samples are round, indicating a proper cutting angle, we speculate
that the filaments in these mutants may not be oriented properly,
so that they get cut at an angle. As mentioned, sarcomeric
structures are observed in longitudinal section, so obviously thick
and thin filaments are present. However there may be subtle
defects in how the filaments line up, caused by excess amounts of
protein, which could interfere with proper filament alignment.
04624 has an intermediate phenotype; the increases in transcript
levels are comparable to 05342, but the filament structure begins
to come into focus, although it is not as sharply defined as it is in
R3 myofibrils. 01640 does not fit in neatly here, as the
transcription phenotype is weaker than 04624, but the myofibril
filament structure is diffuse and does not come into focus.
These differing phenotypes argue against a simple model where
an increase in the amount of structural proteins is the direct cause
of an increase in myofibril diameter. This suggests an additional
function for CF2 that involves sensing/control of myofibril size, in
addition to insuring proper filament ratios. Our data show a small
but significant increase in myofibril diameter in several of the CF2
mutants over wild type. Even in the case of a mutant such as R3,
where the filament balance appears to be restored, and the
hexameric filament pattern is intact and properly aligned, the
increase in myofibril size could be suboptimal for flight, as it could
mean less room for mitochondria. Such mutant flies could be
capable of short bursts of flight, but lack endurance for longer
flights. There is one other report in the literature of a mutant that
increases myofibril diameter, flt H [20]. These flies are flightless,
but there were other defects observed in addition to increased
myofibril diameter, such as disorganized filaments and defects in
Z-bands, which are not observed in R3 or 04624 mutants. The
gene corresponding to the flt H mutation has not been identified,
so nothing is known at the molecular level about its role in flight
muscle development.
CF2 functions in adult muscles are not the same as in
embryonic muscles
In the embryonic and larval somatic muscles, CF2 plays a role
as a transcriptional activator. In cooperation with Mef2, it
activates transcription of a number of different structural genes.
However, in the developing IFM, our data point to an opposite
role. It should be noted that muscle genes that are activated
synergistically by Mef2 and CF2 tend to be expressed in both the
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expressed in the IFM, distinct from the 57B actin gene expressed in
larval muscle. There are putative CF2 binding sites in the first
intron of Act88F, but no putative Mef2 sites nearby. We see an
increase in Act 88F mRNAs with CF2 loss of function
(hypomorphic mutant background or 88F.CF2-RNAi). We also
observe repression of the Act 88F reporter. These data point to a
likely role for CF2 as a direct transcriptional repressor of Act88F.
The use of an 88F-GAL4 driver raises a question because it shares
most if not all of its sequences with the 88F-GFP reporter: would
not the ectopic CF2 negatively feedback and repress its own
expression? We suspect that it most likely does, but not before such
a massive overexpression of CF2 (as the 88F enhancer is very
strong, [21]) does its damage and disrupts IFM development.
Because of the potential problems with negative feedback, we also
tried a mhc-GAL4 driver (made from the F3-580 upstream
fragment diagrammed in Fig. 6A) to drive ectopic CF2 expression,
a reporter that is not quenched by ectopic CF2. The wild type CF2
construct had a milder effect with this driver, resulting in IFM
noticeably thinner than wild type, but intact from anterior to
posterior, in contrast to the effects of the 88F-GAL4 driver.
CF2[A40] behaved the same with both drivers, causing an almost
total ablation of muscle tissue. The severity is most likely due to the
removal of the phosphorylation site, resulting in a protein that
cannot be controlled by shuttling it out of the nucleus [18].
Tn I transcript levels are also altered by hypomorphic CF2
mutations, although we cannot say with our present data whether
this effect is direct or indirect. Previous studies [22] demonstrated
that the overexpression of Tn I caused downregulation of the
transcription of other thin filament genes, which implies a system
of coordinate regulation of thin filament genes. CF2 could be
acting directly on this gene or the effect could be indirect as a
response to alterations in level of Act 88F transcripts. It has been
reported that the 05342 and 08941 mutant lines exhibit a decrease
in Tn I transcript levels in embryos, pupae, and adults [14], which
appears to be in contradiction with our results. The conflicting
results may be explained by the differences in how the experiments
were performed. We used a primer set from Tn I exons 3 and 4 for
our qPCR, which would detect only the IFM-specific isoform of
Tn I. The earlier studies [14] used primers from Tn I exons 7 and
8, which would amplify all Tn I transcripts. It is possible that a
strong downregulation in the non-IFM muscles of the CF2
mutants could mask an increase in Tn I transcript in the IFM.
Despite the same kind of effects observed on mhc mRNAs as
seen with Act 88F and Tn I, we have no evidence for a direct role
for CF2 in the regulation of this gene in the IFM. We tested four
different mhc reporters (three with known mhc enhancer regions) in
CF2 gain of function backgrounds, and found no negative effects
on GFP expression such as we observed with the Act88F-GFP
reporter. Intronic mhc enhancers have been reported [19] and we
have not tested any of these. But the enhancers we did test were
strong drivers of GFP expression, and one of them (F4-678) even
had a close grouping of Mef2 and CF2 sites, which likely
accounted for strong larval somatic muscle expression. It is
unlikely that CF2 could be causing changes in mhc levels by
affecting an untested enhancer while having no effects on the
enhancers we found, but we cannot completely rule out the
possibility that we may have separated IFM enhancers away from
more distant regulatory elements.
CF2 may ‘‘fine tune’’ filament stoichiometry
In mhc or Act88F heterozygotes, there is no upregulation of the
remaining wild type copy sufficient to correct the imbalance in
filament stoichiometry. This could mean that there is no system for
such upregulation, or alternatively, any existing system is not
strong enough to reverse that great an imbalance. It is interesting
to note that in Mhc[1]/+ IFM, the myofibrils are , 30% smaller
than wild type [2], which could represent a not quite successful
attempt by such a putative system to regain proper filament ratios.
In contrast, two of the strongest CF2 mutants (as measured by CF2
protein level) have wild type-like hexagonal arrangements of
filaments, in myofibrils that are up to 50% to 60% larger than wild
type. While we have examined only one thick filament gene and
two thin filament genes, it is likely that expression of other
structural genes is also modulated, directly or indirectly. It has
been noted that CF2 is not absolutely required for initiation of
expression of embryonic muscle genes, but rather it functions to
modulate levels of gene expression [13,14]. CF2 may play a similar
role in the control of Act88F expression, except as a repressor in
the IFM context. As a modulator, a reduction in its function would
have a milder effect, at least in the cases of alleles such as 04624
and R3, an effect possibly weak enough to allow correction within
the capabilities of a potential stoichiometry sensing/maintenance
system. The phenotypes of these two mutants could present an
opportunity to screen for genes involved in sensing and/or
maintaining myofibril size or filament stoichiometry, by providing
a sensitized background.
Materials and Methods
Fly stocks and genetics
All fly stocks were raised on standard media at 22uC unless
otherwise specified. yw[67c23] served as the wild-type control, CF2
mutant stocks CF2[KG05342] and CF2[KG08941] were obtained
from the Bloomington Stock Center (University of Indiana,
Bloomington IN), CF2[c04624] and CF2[c01640] from the
Harvard Exelixis collection (Harvard Medical School, Boston
MA), and UAS-CF2-RNAi (11924-R2) from the National Institute
of Genetics (Mishima, Shizuoka, Japan). The CF2[KG08941-R3]
mutant was generated by P-element excision of the CF2[KG08941]
stock. The mhc-GFP [23] and UAS-CF2-II[wt] and UAS-CF2-
II[A40] strains [18] have been described previously.
Construction of IFM GAL4 driver lines
A 1.3 kb fragment of Act88F upstream region was amplified via
PCR using the primers 59-ggatccaaataaaacgctttgggaatgcc-39 and
59-ggatccttcgacattgaggtcgcactc-39. The fragment was cloned into a
GAL4 vector described previously [24] and used to make
transgenic strains by the standard methodology. Transformant
lines were tested for IFM expression by crossing to UAS-GFP.
GFP expression is first observed in the IFM at around 40 hours
APF (after pupa formation), and in the upper legs of pharate
adults, a pattern reported previously [25]. A chromosome II line,
81B, was recombined with Act88F-GFP (fly line from S. Bernstein)
to produce line 81B-13. A chromosome III line, 69, was
recombined with a mhc-GFP (from E. Chen) to produce line 69-
5. The mhc-GAL4 driver was made with a 580 bp upstream
fragment that first shows IFM expression at about 40 hours APF
(see Figs. 6A and B). A mhc-GAL4, mhc-RFP recombinant line
was made via standard techniques.
Immunostaining of adult IFM
Adults were fixed using the high-octane fixation protocol (R.
Carthew). IFM were stained with anti-CF2 antibody (1:1000) and
a biotinylated goat anti-rabbit 2u antibody (1:1000, Vector,
Burlingame, CA). Photographs were taken with a Zeiss Axioplan
2 microscope and digital camera using AXIOVISION V3.1
software.
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RNA from whole flies of the appropriate genotype was
purified using TriZol (Invitrogen, Carlsbad, CA), and treated
with RQ1 DNAse (Promega, Madison, WI) to remove any
residual genomic DNA. The Superscript II cDNA kit (Invitro-
gen) was used to make cDNA. All qPCR reactions (total volume
o f1 0u l )w e r ed o n ei nt r i p l i c a t ew i t ht h eA p p l i e dB i o s y s t e m s
(Foster City, CA) SYBR Green Master Mix, 400 ng of cDNA,
50 nM primers, in an Applied Biosystems 7500 Fast Real Time
PCR System using the 7500 v2.0.1 software. The primers (exact
sequences available upon request) were designed to include
flight muscle specific exons when applicable (exon 3 for Tn I and
exon 11e for mhc). Measurement of GAPDH1 RNA levels was
used as the reference.
RT-PCR
RNA and cDNA from freeze-dried thoraces, dissected IFM, or
whole flies was prepared as described previously [26]. The
sequences of the primers used are available upon request.
Paraffin sections
Embedding and sectioning of adult thoraces was done as
described previously [26]. Photographs were taken as described
above with a GFP filter.
TEM of flight muscles
Indirect flight muscles were prepared from 1 to 2 day old adults
for transmission electron microscopy and photographed as
described previously [26]. Myofibril sizes were quantified by
counting the thick filaments of 13 single myofibrils magnified at
60,000X for each genotype. Differences from wild type were tested
for statistical significance with student’s t-test.
Construction of mhc and Act88F reporters
The 88Factin reporter was made by inserting the 1.3 kb
fragment used for construction of the GAL4 driver into a Pelican
vector with the GFP region replaced with an RFP construct (Ds-
Red from BD Biosciences, San Jose, CA).
A 9-kb region upstream of the mhc gene was amplified via PCR
to produce a series of overlapping fragments (primer sequences
available upon request). These fragments were cloned into the
Green Pelican vector and used to create transgenic fly strains via
standard techniques. Transgenic animals were monitored under
fluorescent light during the larval and pupal stages to determine
any muscle expression pattern. Live animals expressing GFP or
RFP were photographed with a Leica MZFLIII Stereomicroscope,
using ImagePro 6.0.
Western blotting
Freeze dried IFM or whole thoraces of each genotype were
pooled, ground in liquid nitrogen, and resuspended in 50 ml
dH2O/50 ml Western sample buffer (125 mM Tris 6.8, 6% SDS,
20% glycerol, 0.025% bromophenol blue, 10% b-mercaptoetha-
nol), and heated to 100uC for 10 minutes. Samples were resolved
on 8% polyacrylamide gels and transferred to Immobilon-P
(Millipore, Billerica, MA) using standard protocols. Membranes
were incubated overnight at 4uC with CF2 antibody (a polyclonal
that detects all three isoforms) at a dilution of 1:15,000 or actin
antibody (MAB 150 1, Millipore) at a dilution of 1:1000.
Secondary antibody (anti-rabbit-HRP for CF2, anti-mouse-HRP
for actin, Pierce, Rockford, IL) was used at a dilution of 1:4000.
Protein bands were visualized using SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce).
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